Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance
Executive Summary
Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.
You may also be interested in...
Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
Rubraca Ovarian Cancer Maintenance Approval Brings PARP Inhibitor Parity On Broad Indication
US FDA approval of Rubraca's all-comers maintenance therapy for platinum-sensitive ovarian cancer continues model that Zejula and Lynparza used for a broad maintenance indication, with data broken out for germline BRCA mutation-positive patients in the clinical trials section of labeling.
Reimbursement Challenge: CMS Questions Azedra Endpoint While Still Under FDA Review
Progenics' radiopharmaceutical using novel surrogate endpoint for US FDA review; CMS seems unimpressed, which doesn't bode well for new technology add-on payment.